This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2010;49(1):104-6.

doi: 10.3109/02841860903147532.

Sorafenib induces partial response in metastatic medullary thyroid carcinoma

Elena Spector¹, Michael J Franklin, Alexander M Truskinovsky, Arkadiusz Z Dudek

Affiliations

PMID: 19711206
DOI: 10.3109/02841860903147532

Case Reports

Sorafenib induces partial response in metastatic medullary thyroid carcinoma

Elena Spector et al. Acta Oncol. 2010.

. 2010;49(1):104-6.

doi: 10.3109/02841860903147532.

Authors

Elena Spector¹, Michael J Franklin, Alexander M Truskinovsky, Arkadiusz Z Dudek

Affiliation

¹ Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA. dudek002@umn.edu

PMID: 19711206
DOI: 10.3109/02841860903147532

No abstract available

PubMed Disclaimer

Similar articles

Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma.
Aller S, Popescu A, Rao S, Morgan E, Gosiengfiao Y. Aller S, et al. Pediatr Blood Cancer. 2012 Jan;58(1):98-100. doi: 10.1002/pbc.23032. Epub 2011 Jun 30. Pediatr Blood Cancer. 2012. PMID: 21721105
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Procopio G, Verzoni E, Gevorgyan A, Mancin M, Pusceddu S, Catena L, Platania M, Guadalupi V, Martinetti A, Bajetta E. Procopio G, et al. Oncology. 2007;73(3-4):204-9. doi: 10.1159/000127387. Epub 2008 Apr 16. Oncology. 2007. PMID: 18418013
Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
Diamantis ML, Chon SY. Diamantis ML, et al. J Drugs Dermatol. 2010 Feb;9(2):169-71. J Drugs Dermatol. 2010. PMID: 20214183
Sorafenib: delivering a targeted drug to the right targets.
Flaherty KT. Flaherty KT. Expert Rev Anticancer Ther. 2007 May;7(5):617-26. doi: 10.1586/14737140.7.5.617. Expert Rev Anticancer Ther. 2007. PMID: 17492926 Review.
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B. Strumberg D, et al. Oncologist. 2007 Apr;12(4):426-37. doi: 10.1634/theoncologist.12-4-426. Oncologist. 2007. PMID: 17470685 Review.

See all similar articles

Cited by

Occult primary medullary thyroid carcinoma presenting with pituitary and parotid metastases: case report and review of the literature.
Conway A, Wiernik A, Rawal A, Lam C, Mesa H. Conway A, et al. Endocr Pathol. 2012 Jun;23(2):115-22. doi: 10.1007/s12022-012-9200-4. Endocr Pathol. 2012. PMID: 22371144 Review. No abstract available.
The Use of Sorafenib in the Thyroid Cancer.
Zygulska AL, Krzemieniecki K, Sowa-Staszczak A. Zygulska AL, et al. Eur Endocrinol. 2013 Mar;9(1):28-31. doi: 10.17925/EE.2013.09.01.28. Epub 2013 Mar 15. Eur Endocrinol. 2013. PMID: 30349607 Free PMC article. Review.
Medullary carcinoma of the thyroid with axillary metastasis: a case report.
Ozdemir M, Makay O, Simsir I, Ertan Y, Icoz G, Saygili F, Akyildiz M. Ozdemir M, et al. Int Surg. 2015 Mar;100(3):390-3. doi: 10.9738/INTSURG-D-13-00274.1. Int Surg. 2015. PMID: 25785315 Free PMC article.

Publication types

Actions

MeSH terms

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information